LeonaBio is hosting a virtual event on April 29, 2026, featuring leading breast cancer experts to discuss lasofoxifene, a drug targeting treatment-resistant ER+, HER2-, ESR1-mutated metastatic breast cancer. The company expects to complete enrollment in its Phase 3 ELAINE-3 trial by late 2026, with data anticipated in the second half of 2027. Lasofoxifene has shown promising results in earlier trials, potentially offering a new standard of care for this genetically defined patient group with limited treatment options. This event highlights the evolving treatment landscape and unmet needs in metastatic breast cancer care.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
